Renesis Partners with Enzyme to Bring Institutional-Grade Reporting to Tokenized Funds

The Tokenized Fund Stack Is Maturing

Tokenized fund infrastructure stopped being a future concept a while ago. Today, regulated funds are operating on public blockchains at multi-billion-dollar scale, major asset managers have launched production products, and traditional market infrastructure providers are building tokenization directly into their servicing and settlement stacks. It's an active, growing market, and Enzyme has been one of the protocols pushing it forward the fastest.

With Enzyme Onyx now live and already in production with more than 15 managers, and with recent expansions to networks like Canton and Rayls alongside institutional partnerships such as CV5 Capital, Enzyme has built a comprehensive suite of products to create and manage next-generation financial products and strategies.

Renesis is announcing a partnership with Enzyme, bringing together Enzyme's tokenized fund infrastructure and Renesis's portfolio and reporting layer for institutional crypto funds. The partnership starts with a deep technical integration between the two platforms, giving fund managers operating on-chain a more complete infrastructure stack.

Why Enzyme

Enzyme Onyx gives fund managers something that's genuinely hard to build well: a complete, non-custodial tech stack for wrapping a strategy into a tokenized, investor-ready Vault Share, one that works across custody providers, asset classes, and increasingly across chains. Managers aren't locked into a single custody model or a single network. They can run a strategy through Safe, Fireblocks, or a prime broker of their choice, price it through Onyx, and issue shares that institutional allocators can actually hold, transfer, and redeem on-chain.

That's a meaningful unlock for the fund industry. Tokenizing a fund's shares means capital can move faster, subscriptions and redemptions can settle without the multi-day friction of traditional fund administration, and a strategy that used to require a fund admin, a transfer agent, and a NAV calculation agent can now run on infrastructure that does all three natively. It also widens who a fund can raise from in the first place. A tokenized share is easier to distribute to allocators who are already operating on-chain, easier to move across custody providers without a re-onboarding process each time, and easier to hold in a portfolio that mixes traditional and digital assets. For a manager trying to grow AUM, that's not just an operational upgrade, it's a distribution one.

Enzyme's recent moves, bringing Onyx to Canton for institutional-grade settlement, expanding to Rayls, integrating Chainlink's CRE for automated compliance and reporting, all point the same direction: on-chain fund infrastructure that's being built to actually meet institutional standards, not just crypto-native ones.

Where Renesis Fits In

Tokenized shares solve issuance. They don't, on their own, solve reporting. A Vault Share prices a fund's NAV, but an LP still wants a report that shows what their allocation is doing next to everything else the manager runs, an auditor still wants a clean record, and a risk team still wants consistent data across every venue the fund touches.

That's the layer Renesis has built on top of Enzyme. Inside the Renesis LP Reporting Workspace, a fund can set Strategy Mode to Vault-derived and auto-detect strategies directly from on-chain vault share tokens, Enzyme Vault Shares among them, without a manager manually re-entering the position, its fee terms, or its inception date.

From there, Renesis generates a one-page Investor Report straight from that live data: NAV, AUM, PnL for the period and since inception, annualized returns, and a fee summary, broken out per strategy and rendered as a clean, print-ready PDF a manager can hand to an LP without a weekend of manual reconciliation first.

In practice, that means a fund running capital through an Enzyme vault can see that position sitting inside the same portfolio as their CEX balances, their staking positions, and every other DeFi allocation they hold, priced, reconciled, and ready to report on, in real time.

What Comes Next for Tokenized Funds

This partnership is only the beginning. Enzyme has built the issuance and administrating layer for tokenized funds. Renesis is building the reporting and portfolio layer that sits on top of it. Together, that starts to look like a more complete stack: a manager can structure and tokenize a strategy through Enzyme, run it through whatever custody setup fits their operation, and report on it, alongside everything else in the fund, through Renesis.

We're excited about this partnership as a first step toward Renesis becoming part of what Enzyme can offer its own institutional clients directly, a reporting and portfolio layer available to managers building on Onyx from day one, not something they have to go find separately. That's the deeper integration work ahead, as Enzyme continues to expand across chains and asset classes, and Renesis continues to build out the reporting and analytics layer for funds operating on-chain. As tokenized funds move from early adoption to standard practice, the managers who win LP trust will be the ones who can show, cleanly and on demand, exactly what they hold and how it's performing. That's the problem Renesis and Enzyme are solving together.

Renesis is a unified portfolio management and execution platform for liquid crypto funds delivering real-time NAV and protocol-level tracking across 90+ integrations spanning CeFi and DeFi, including Enzyme.